SCHEMBL8551633

SCHEMBL8551633

Oc1cc(CCl)nc(O)n1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22738245 0.80
SCHEMBL11362095 0.79 SMN1; SMN2 (0.34) SMN1; SMN2KMT2A
SCHEMBL22312575 0.79 SMN1; SMN2 (0.34) SMN1; SMN2KMT2AKDM4ETDP1
SCHEMBL10617526 0.77 HSP90AB1 (0.39) SMN1; SMN2KMT2AKDM4E
SCHEMBL8545461 0.77 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AKDM4ETDP1
SCHEMBL4273108 0.76 NOS3 (0.39)
SCHEMBL11091306 0.74 SMN1; SMN2 (0.32) SMN1; SMN2
SCHEMBL1271823 0.73 POLB (0.39) SMN1; SMN2KMT2AKDM4ETDP1
SCHEMBL6689462 0.73 KDM4E (0.36) SMN1; SMN2KMT2AKDM4ETDP1
SCHEMBL4988333 0.73 SMN1; SMN2 (0.34) SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118684633-A Androgen receptor modulators and methods of use thereof 埃萨制药股份有限公司 2024-09-24 CN disclosed
CN-113195441-B Androgen receptor modulators and methods of use thereof 埃萨制药股份有限公司 2024-07-12 CN disclosed
WO-2024125451-A1 PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
CN-117940433-A Quinoline furan derivative and application thereof 瑞石生物医药有限公司 2024-04-26 CN disclosed
WO-2024044731-A1 DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY MATCHPOINT THERAPEUTICS INC. (US) 2024-02-29 WO disclosed
WO-2024044731-A1 DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY MATCHPOINT THERAPEUTICS INC. (US) 2024-02-29 WO disclosed
WO-2023025298-A1 QUINOLINOFURAN DERIVATIVE AND USE THEREOF 瑞石生物医药有限公司 2023-03-02 WO disclosed
WO-2023025298-A1 QUINOLINOFURAN DERIVATIVE AND USE THEREOF 瑞石生物医药有限公司 2023-03-02 WO disclosed
US-20220380325-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2022-12-01 US disclosed
CN-113195441-A Androgen receptor modulators and methods of use thereof 埃萨制药股份有限公司 2021-07-30 CN disclosed
US-20200123117-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA, INC. (CA) 2020-04-23 US disclosed
US-20200123117-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA, INC. (CA) 2020-04-23 US disclosed
EP-0714393-B1 THIAZOLES AS ANTIVIRAL PFIZER (US) 1998-09-23 EP disclosed
US-5789408-A Antiviral thiazoles PFIZER INC. (US) 1998-08-04 US disclosed
EP-0714393-A1 THIAZOLES AS ANTIVIRAL PFIZER INC. (US) 1996-06-05 EP disclosed
WO-1995005378-A1 ANTIVIRAL THIAZOLES PFIZER INC. (US) 1995-02-23 WO disclosed
US-4211562-A Photographic compositions with silver halide solvents containing thioether groups POLAROID CORPORATION (US) 1980-07-08 US disclosed
US-4211559-A Photographic processes and compositions employing thioether containing silver halide solvents TEXAS INSTRUMENTS INCORPORATED (US) 1980-07-08 US disclosed
US-4150228-A PHOTOGRAPHIC COMPLEXING AGENTS POLAROID CORPORATION (US) 1979-04-17 US disclosed
US-4126459-A COMPLEXING AGENT FOR USE IN PHOTOGRAPHY POLAROID CORPORATION (US) 1978-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123117-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE AR, NR5A1, CYP17A1 SMN1; SMN2 4842/4885KMT2A 2406/4885KDM4E 3774/4885
US-20220380325-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE AR, NR5A1, CYP17A1 SMN1; SMN2 4842/4885KMT2A 2406/4885KDM4E 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.